BONE

Journal

Publication Venue For

  • Changes in Dkk-1, sclerostin, and RANKL serum levels following discontinuation of long-term denosumab treatment in postmenopausal women.  123:191-195. 2019
  • Real-world effectiveness of teriparatide on fracture reduction in patients with osteoporosis and comorbidities or risk factors for fractures: Integrated analysis of 4 prospective observational studies.  116:58-66. 2018
  • Quality in dual-energy X-ray absorptiometry scans.  104:13-28. 2017
  • NFAM1 signaling enhances osteoclast formation and bone resorption activity in Paget's disease of bone.  101:236-244. 2017
  • Cardiac actions of fibroblast growth factor 23.  100:69-79. 2017
  • Tgfbr2 is required in osterix expressing cells for postnatal skeletal development.  97:54-64. 2017
  • Cortical bone deficit and fat infiltration of bone marrow and skeletal muscle in ambulatory children with mild spastic cerebral palsy..  94:90-97. 2017
  • Immature myeloid cells are critical for enhancing bone fracture healing through angiogenic cascade.  93:113-124. 2016
  • Admixture mapping of serum vitamin D and parathyroid hormone concentrations in the African American-Diabetes Heart Study.  87:71-77. 2016
  • Analysis of osteoporosis treatment patterns with bisphosphonates and outcomes among postmenopausal veterans.  78:174-185. 2015
  • Non-coding RNAs: Epigenetic regulators of bone development and homeostasis.  81:746-756. 2015
  • Deletion of core-binding factor β (Cbfβ) in mesenchymal progenitor cells provides new insights into Cbfβ/Runxs complex function in cartilage and bone development.  65:49-59. 2014
  • Heparanase inhibits osteoblastogenesis and shifts bone marrow progenitor cell fate in myeloma bone disease.  57:10-17. 2013
  • Osteoporosis medication adherence: Physician perceptions vs. patients' utilization.  55:1-6. 2013
  • Bone healing by endogenous stem cell mobilization.  51:635. 2012
  • Effect of co-morbidities on fracture risk: Findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW).  50:1288-1293. 2012
  • Medication adherence and fracture risk among patients on bisphosphonate therapy in a large United States health plan.  50:870-875. 2012
  • Mobilization of bone marrow mesenchymal stem cells in vivo augments bone healing in a mouse model of segmental bone defect.  50:1012-1018. 2012
  • Corrigendum to "Bisphosphonates and glucocorticoid osteoporosis in men: Results of a randomized controlled trial comparing zoledronic acid with risedronate" [Bone 50 (2012) 289-295].  50:811. 2012
  • Bisphosphonates and glucocorticoid osteoporosis in men: Results of a randomized controlled trial comparing zoledronic acid with risedronate.  50:289-295. 2012
  • Short-term physical activity intervention decreases femoral bone marrow adipose tissue in young children: A pilot study.  50:23-27. 2012
  • Molecular subtypes of osteosarcoma identified by reducing tumor heterogeneity through an interspecies comparative approach.  49:356-367. 2011
  • Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW).  49:493-498. 2011
  • Corrigendum to "Cost burden of second fracture in the US Health System" [Bone 48 (2011) 828-836].  48:1429. 2011
  • Cost burden of second fracture in the US Health System.  48:828-836. 2011
  • Deletion of insulin receptor in chondrocytes sensitizes IGF-1 signaling and action.  47:S446-S446. 2010
  • Trpv6 mediates intestinal calcium absorption during calcium restriction and contributes to bone homeostasis.  47:301-308. 2010
  • Effect of HIP/ribosomal protein L29 deficiency on mineral properties of murine bones and teeth.  47:93-101. 2010
  • Bone formation markers in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.  46:929-934. 2010
  • NFATc1 mediates HDAC-dependent transcriptional repression of osteocalcin expression during osteoblast differentiation.  45:579-589. 2009
  • Hypoxia and HIF-1α expression in the epiphyseal cartilage following ischemic injury to the immature femoral head.  45:280-288. 2009
  • Mecp2 deficiency decreases bone formation and reduces bone volume in a rodent model of Rett syndrome.  45:346-356. 2009
  • Zfp521 antagonizes Runx2, delays osteoblast differentiation in vitro, and promotes bone formation in vivo.  44:528-536. 2009
  • Congenital pseudarthrosis of neurofibromatosis type 1: Impaired osteoblast differentiation and function and altered NF1 gene expression.  44:243-250. 2009
  • DSPP effects on in vivo bone mineralization.  43:983-990. 2008
  • Cyclosporin A elicits dose-dependent biphasic effects on osteoblast differentiation and bone formation.  40:1502-1516. 2007
  • A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density.  40:1238-1243. 2007
  • Evolving gene therapy approaches for osteosarcoma using viral vectors: Review.  40:797-812. 2007
  • Identification of the type II Na+-Pi cotransporter (Npt2) in the osteoclast and the skeletal phenotype of Npt2-/- mice.  29:467-476. 2001
  • International Standard Serial Number (issn)

  • 8756-3282
  • Electronic International Standard Serial Number (eissn)

  • 1873-2763